Repair Biotechnologies Demonstrates Rapid Reversal of Atherosclerosis in Mouse Models

Repair Biotechnologies, Inc. ( announced today that its lipid nanoparticle (LNP) / messenger RNA (mRNA) therapy has rapidly reversed the progression of atherosclerosis in mouse models applicable to both the rare genetic condition of familial hypercholesterolemia as well as atherosclerosis in the broader population. Repair Biotechnologies develops gene therapies based on the proprietary Cholesterol Degrading […]

Repair Biotechnologies Announces 48% Reversal of Atherosclerotic Plaque Lipids in a Preclinical Mouse Study

BOSTON, M.A.–Repair Biotechnologies, Inc. announced today breakthrough results from a preclinical study of the Cholesterol Degrading Platform (CDP) in a mouse model of late-stage cardiovascular disease. A single treatment of the CDP drug developed by Repair Biotechnologies resulted in a 48% reversal of the obstruction of aortic blood vessels by lipid-based plaque. Additionally, Repair Biotechnologies […]